Publicacions en què col·labora amb Gema Fruhbeck Martínez (188)

2023

  1. Antagonic effect of ghrelin and LEAP-2 on hepatic stellate cell activation and liver fibrosis in obesity-associated nonalcoholic fatty liver disease

    European journal of endocrinology, Vol. 188, Núm. 7, pp. 564-577

  2. BMI-based obesity classification misses children and adolescents with raised cardiometabolic risk due to increased adiposity

    Cardiovascular Diabetology, Vol. 22, Núm. 1

  3. Corrigendum: Increased levels of interleukin-36 in obesity and type 2 diabetes fuels adipose tissue inflammation by inducing its own expression and release by adipocytes and macrophages(Front. Immunol., (2022), 13, (832185), 10.3389/fimmu.2022.832185)

    Frontiers in Immunology

  4. Effect of guanylin peptides on pancreas steatosis and function in experimental diet-induced obesity and after bariatric surgery

    Frontiers in Endocrinology, Vol. 14

  5. Hepatic p63 regulates glucose metabolism by repressing SIRT1

    Gut, Vol. 72, Núm. 3, pp. 472-483

  6. Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial function

    Molecular Metabolism, Vol. 75

  7. Increased Aquaporin-7 Expression Is Associated with Changes in Rat Brown Adipose Tissue Whitening in Obesity: Impact of Cold Exposure and Bariatric Surgery

    International Journal of Molecular Sciences, Vol. 24, Núm. 4

  8. Increased Expression Levels of Netrin-1 in Visceral Adipose Tissue during Obesity Favour Colon Cancer Cell Migration

    Cancers, Vol. 15, Núm. 4

  9. Molecular and cellular mechanisms underlying the hepatoprotective role of ghrelin against NAFLD progression

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 4, pp. 833-849

  10. Neddylation of phosphoenolpyruvate carboxykinase 1 controls glucose metabolism

    Cell Metabolism, Vol. 35, Núm. 9, pp. 1630-1645.e5

  11. Sex- and Age-Dependent Changes in the Adiponectin/Leptin Ratio in Experimental Diet-Induced Obesity in Mice

    Nutrients, Vol. 15, Núm. 1

  12. Uroguanylin prevents hepatic steatosis, mitochondrial dysfunction and fibrosis in obesity-associated NAFLD

    Metabolism: Clinical and Experimental, Vol. 147